At-Home Blood Collection Devices Market

The value of the at-home blood collection devices market is estimated to be USD 93 million in 2024 and is likely to reach USD 135 million by 2029 at a CAGR of 7.6% from 2024 to 2029. Several factors drive the At-home blood collection devices market. Improvement in device technology is making them less invasive, user-friendly, and less painful to the consumer; for example, bladeless or needle-free sampling. Second, increasing consumer awareness and demand for proactive health management has a positive influence on the market, as people like to ensure convenient ways of monitoring their health. Regulatory approvals and setting of new standards for these devices ensure their safety and efficiency, creating consumer confidence. Efforts are also being put in at the manufacturing and technology ends to reduce their prices, making them more affordable to people.

Global Forecast for the At-Home Blood Collection Devices Market through 2029

To know about the assumptions considered for the study, Request for Free Sample Report

Promising Opportunities in the At-Home Blood Collection Devices Market

At-Home Blood Collection Devices Market Dynamics

DRIVER: Rising burden of chronic disorders and life-style-related health conditions

The demand for at-home blood collection devices will clearly increase with the increase in chronic illnesses and lifestyle disorders. Some key biomarkers, such as blood glucose, cholesterol, and inflammatory indicators, need regular monitoring to administer a host of chronic diseases like diabetes, cardiovascular conditions, and blood pressure. at-home blood collection devices provide an easy, convenient way for people to frequently check these health metrics without having to visit health centers many times. This is particularly very useful for patients with long-term conditions, in that it allows one to fit monitoring easily into their daily routine since they require frequent health checks to minimize risks and effectively handle the conditions. Moreover, it is the guarantee of privacy and comfort during home testing that attracts more and more people who seek to manage their lives in a more personalized and proactive way toward healthcare.

RESTRAINT: Uncontrolled use of products for blood collection at home

There is a huge problem of lack of regulation around certain products used for blood collection at home. Some laboratories bypass this by using unapproved products for the sake of convenience. These are products include, tubes, needles, syringes, and some lancets, which are mean for professional use in a sterile environment and need proper disposal. In no way are they for home use, and associated health risks are posed if used outside their context. In this way, uncontrolled practice affects the standards and points out the serious gap in the present regulatory framework.

OPPORTUNITY: Growth opportunities in emerging economies

The key players in the at-home blood collection devices market are expected to find growth opportunities in developing economies such as India, Brazil, and Mexico. This has been attributed to a large patient population, high prevalence of diseases, improved healthcare infrastructure, rising disposable income, and increasing medical tourism in these nations. On top of the factors discussed above, the Asia Pacific has risen to the surface as an adaptive and business-friendly hub due to less stringent regulations.

Most of the players concentrate on emerging markets, as the US and European markets are saturated. The large investments in research related to healthcare and life sciences in emerging markets act as a significant factor in upgrading the infrastructure of laboratories of such countries.

CHALLENGE: Low access to microsampling devices in resource-limited settings

One of the major restraints for the microsampling devices market is the non-accessibility of at-home blood collection devices in resource-limited settings. In spite of increasing demand for at-home blood collection devices, amplified by their technological advances, a raft of factors restrains their widespread adoption in developing or resource-limited countries. In many resource-limited settings, supply chains for these devices are not well established, and this has been associated with irregularity and delays in reaching the end users. Another major barrier is lack of awareness and education among healthcare professionals and the general populace on the benefits and usage of microsampling devices.

Ecosystem/Market Overview of At-Home Blood Collection Devices

“Fingerstick held the largest share of the at-home blood collection devices market in 2023, by collection method.”

The segmentation of the at-home blood collection devices market based on the method of collection includes fingerstick, push-button, and others. In 2023, the fingerstick segment captured the largest share of the at-home blood collection devices market. Fingerstick devices have a non-complex and simple user interface and require minimum training. Users can collect the blood on their own without professional guidance. These factors make frequent monitoring and testing easy at home. As a result, fingerstick devices dominate the at-home blood collection devices market.

“Self-collection devices segment accounted for the largest share of the market in 2023, by device type.”

On the basis of device type, the at-home blood collection devices market is segmented into self-collection and professional collection devices. The self-collection devices segment is expected to account for the largest share of the at-home blood collection devices market in 2023. Due to increasing awareness about preventive healthcare and regular health monitoring, demand for self-collection devices has risen. Many prefer the convenience of self-monitoring of health. Growth in this segment of the market is majorly driven by the rising trends of diabetes and other lifestyle diseases.

“Health screening & preventive health segment dominated the at-home blood collection devices market in 2023, based on application.”

The segmentation of the at-home blood collection devices market on the basis of applications includes health screening & preventive health, disease diagnostics, clinical trials & research, and other applications. The health screening & preventive health segment dominated a major share in the at-home blood collection devices market in 2023. Increased demand for proactive health management and consumer awareness is driving the growth of this segment. With increased chronic and lifestyle-related diseases, the focus is more on preventive health measures. At-home blood collection devices facilitate close tracking of key health indicators—blood sugar and lipid levels—which reduces the risk of complications through continuous disease management. Regular screening can identify potential issues before they become serious. At-home blood collection devices make self-sampling easy and efficient for people to maintain preventive health practices and ensure that one's health status is being monitored regularly.

“North America accounted for the largest share of the at-home blood collection devices market in 2023.”

The at-home blood collection devices market has been divided into six main geographical regions: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and GCC countries. In 2023, it is anticipated that North America will be at the forefront of the market. The infrastructures in North America, essentially the US and Canada are very developed for diagnosis, treatment, and research pertaining to chronic disorders. This kind of set-up would facilitate easy adoption of new technologies like at-home blood collection devices.

Regional Analysis of the At-Home Blood Collection Devices Market

To know about the assumptions considered for the study, download the pdf brochure

The major players in this market are Tasso, Inc. (US), Trajan Group Holdings Limited (Australia), YourBio Health, Inc. (US), and Capitainer (Sweden). These players lead the market because of their extensive product portfolios and wide geographic presence.

Scope of the At-Home Blood Collection Devices Market Report

This report categorizes the at-home blood collection devices market based on product, collection method, sample type, usability, device type, application, and region:

By Product

• Fingerstick Blood Collection Kits
• DBS Collection Kits
• Lancets
• Other Products

By Collection Method

• Fingerstick Method
• Push-button Method
• Other Methods

By Sample Type

• Dried Blood Samples
• Liquid Blood Samples

By Usability

• Single-use Blood Collection Devices
• Reusable Blood Collection Devices

By Device Type

• Self-collection Devices
• Professional Collection Devices

By Application

• Disease Diagnostics
• Health Screening & Preventive Health
• Clinical Trials & Research
• Other Applications

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of LATAM
• Middle East & Africa
  • GCC Countries

Latest Developments in the At-Home Blood Collection Devices Market

• In June 2024, Lindus Health and Tasso, Inc. collaborated to reduce patient burden in clinical trials requiring blood collection. As per the collaboration, Lindus Health will adopt Tasso’s painless remote blood collection technology for sponsors seeking simple, cost-effective blood collection during their clinical trials. This innovative method allows participants to collect blood samples at home, eliminating the need for a mobile phlebotomist or nurse.
• In November 2023, Randox Health, a provider of at-home and in-clinic health tests as part of Randox and Tasso, partnered to offer at-home healthcare diagnostic testing powered by Tasso’s innovative blood collection technology.
• In October 2023, YourBio Health, Inc. (US) received further regulatory approval for its TAP Micro Select blood collection device with certification for CE Marking.
• In January 2023, Capitainer collaborated with AstraZeneca. AstraZeneca R&D Gothenburg will use a novel device from Capitainer to develop protocols for biomarkers relevant to AstraZeneca’s clinical drug programs. The collaboration seeks to establish protocols for biomarkers pertinent to AstraZeneca’s clinical drug programs, utilizing Capitainer’s innovative self-sampling product that delivers cell-free blood. This partnership enables the implementation of new, patient-centric sampling solutions.
• In December 2022, Capitainer (Sweden) launched Capitainer B 50, a product for the self-sampling of blood. The sampling card can collect five times as much blood as its predecessor. It enables analysis requiring larger blood volumes for accurate analytical sensitivity.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst